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Abstract 
Background: Adiponectin has multiple functions including insulin sensitization, anti-inflammation and antiathero-
genesis in various organs. Adiponectin activates 5′-adenosine monophosphate-activated protein kinase (AMPK) and 
peroxisome proliferator-activated receptor (PPAR)α via the adiponectin receptor (AdipoR) 1 and 2, which are critical 
for regulating lipids and glucose homeostasis and for controlling oxidative stress. We investigated whether resveratrol 
can inhibit renal damage in type 2 diabetic db/db mice and the underlying mechanisms of its effects.
Methods: Four groups of male C57 BLKS/J db/m and db/db mice and human glomerular endothelial cells (HGECs) 
were used. Resveratrol was administered to diabetic and nondiabetic mice by oral gavage for 12 weeks starting at 
8 weeks of age.
Results: In db/db mice, resveratrol increased serum adiponectin levels and decreased albuminuria, glomerular matrix 
expansion, inflammation and apoptosis in the glomerulus. Resveratrol increased the phosphorylation of AMPK and 
silent information regulator T1 (SIRT1), and decreased phosphorylation of downstream effectors class O forkhead 
box (FoxO)1 and FoxO3a via increasing AdipoR1 and AdipoR2 in the renal cortex. Furthermore, resveratrol increased 
expression of PPARγ coactivator (PGC)-1α, estrogen-related receptor-1α, and phosphorylated acetyl-CoA carboxylase 
and decreased sterol regulatory element-binding protein 1. This effect lowered the content of nonesterified fatty acid 
and triacylglycerol in the kidneys, decreasing apoptosis, oxidative stress and activating endothelial nitric oxide syn-
thase. Resveratrol prevented cultured HGECs from undergoing high-glucose-induced oxidative stress and apoptosis 
by activating the AMPK–SIRT1–PGC–1α axis and PPARα through increases in AdipoR1 and AdipoR2 expression.
Conclusions: These results suggest that resveratrol prevents diabetic nephropathy by ameliorating lipotoxicity, oxi-
dative stress, apoptosis and endothelial dysfunction via increasing AdipoR1 and AdipoR2 expression.
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Background
Diabetic nephropathy (DN) is the most common and 
most rapidly growing cause of end-stage renal dis-
ease. Treatment of DN by renal replacement therapy 
is a major expense, also in Korea [1]. Numerous factors 
including hyperglycemia-induced oxidative stress and 
inflammation contribute to the pathogenesis and pro-
gression of diabetic chronic kidney disease (CKD). Some 
studies have demonstrated that accumulation of lipids in 
the kidneys plays a crucial role in the progression of dia-
betic renal damage [2, 3], suggesting that lipotoxicity of 
free fatty acids or triglycerides and lipotoxicity-induced 
oxidative stress may critically contribute to the pathogen-
esis of diabetic CKD. However, the underlying molecular 
mechanisms of these effects are unclear.
Adiponectin is an adipokine secreted by adipose tis-
sue that is downregulated in insulin-resistant obesity. 
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Adiponectin can suppress oxidative stress and inflam-
mation, leading to antidiabetic and antiatherosclerotic 
effects [4]. Adiponectin protects kidneys by reducing 
albuminuria, which is a reliable marker for renal dysfunc-
tion in diabetes mellitus (DM) [5, 6]. Adiponectin exerts 
its biological effects through adiponectin receptors (Adi-
poR), including AdipoR1 and AdipoR2. AdipoR1 medi-
ates increases in 5′-adenosine monophosphate-activated 
protein kinase (AMPK), and AdipoR2 activates peroxi-
some proliferator-activated receptor (PPAR)α. AdipoR1 
is widely expressed in muscle tissue, while AdipoR2 is 
expressed predominantly in the liver [7, 8]. Studies inves-
tigating the distribution of AdipoR1 and AdipoR2 and 
their function in kidneys suggested that activation of 
AdipoR1 and AdipoR2 could prevent and ameliorate DN, 
especially in type 2 DM.
Resveratrol is a natural plant polyphenol that may tar-
get aging and obesity-related chronic disease by regulating 
inflammation and oxidative stress. Resveratrol is an activa-
tor of AMPK, which is involved in controlling oxidative 
stress and in lipid and glucose homeostasis [9–12]. AMPK 
participates in the regulation of other cellular processes 
including autophagy, apoptosis, and inflammation. Previous 
studies demonstrated that resveratrol alleviated alcoholic 
fatty liver disease in mice by increasing hepatic AdipoR1/R2 
expression [13] and attenuated DN by increasing renal Adi-
poR1 expression in rats with streptozotocin-induced diabe-
tes [14]. In this study, we investigated whether the beneficial 
effects of resveratrol are associated with AdipoR1 and Adi-
poR2 activation in type 2 diabetic db/db mice.
Methods
Experimental methods
Six-week-old male C57BLKS/J db/m and db/db mice 
were purchased from Jackson Laboratories (Bar Harbor, 
ME, USA) and divided into four groups that received 
either 0.5 % carboxymethyl cellulose sodium salt (CMC) 
or resveratrol (Sigma-Aldrich, St. Louis, MO, USA). The 
resveratrol was dissolved in 0.5  % CMC and 20  mg/kg/
day was administered to db/db Res (n = 8) and db/m Res 
(n = 8) mice for 12 weeks starting at 8 weeks of age [9]. 
Control db/db (n =  8) and db/m (n =  8) mice received 
only 0.5 % CMC. At week 20, all animals were anesthe-
tized by intraperitoneal injection of 30 mg/kg tiletamine 
plus zolazepam (Zoletil; Virbac, Carros, France) and 
10  mg/kg xylazine hydrochloride (Rompun; Bayer, Leu-
verkusen, Germany). Mice were euthanized and kidneys 
removed. All experiments including Western blots were 
performed using renal cortex samples. Kidneys were rap-
idly dissected and fixed in normal-buffered 10 % formalin 
for immunohistochemical analyses. Blood was collected 
from the left ventricle and plasma was stored at −70 °C.
Ethics statement
All animal experiments were performed in accordance 
with the Laboratory Animals Welfare Act and the Guide 
for the Care and Use of Laboratory Animals, and were 
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) at the College of Medicine, the Catholic 
University of Korea (CUMC-2012-0118-02). All proce-
dures complied with the Guide for the Care and Use of 
Laboratory Animals (National Institutes of Health Publi-
cation No. 85–23, revised 1996).
Measurement of serum parameters
After 12  weeks of resveratrol treatment, blood glucose 
was measured using an Accu-check meter (Roche Diag-
nostics, St. Louis, MO, USA). Hemoglobin A1c (HbA1c) 
was determined from red cell lysates by HPLC (Bio-Rad, 
Richmond, CA, USA). The concentration of serum adi-
ponectin was determined by ELISA (Biosource, Cama-
rillo, CA, USA). Total cholesterol and triacylglycerol 
(TG) concentrations were measured with an autoana-
lyzer (Hitachi 917, Tokyo, Japan) using commercial kits 
(Wako, Osaka, Japan). Nonesterified fatty acid (NEFA) 
levels were measured with a JCA-BM1250 automatic 
analyzer (JEOL, Tokyo, Japan).
Assessment of renal function, oxidative stress 
and intrarenal lipids
A 24-h urine sample was obtained from mice at 20 weeks 
using metabolic cages, and urinary albumin concentra-
tions were measured by immunoassay (Bayer, Elkhart, IN, 
USA). Plasma and urine creatinine concentrations were 
measured using HPLC (Beckman Instruments, Fullerton, 
CA, USA). To evaluate oxidative stress, we measured the 
24-h urinary 8-hydroxy-2′-deoxyguanosine (8-OH-dG; 
OXIS Health Products, Inc., Portland, OR, USA) and 
8-epi-prostaglandin F2α (8-epi-PGF2α; Oxis Research, 
Foster City, CA, USA) levels. Kidney lipids were extracted 
using the method of Bligh and Dyer with slight modifica-
tions as previously described (Waco, Osaka, Japan) [15]. 
Furthermore, to evaluate the effect of resveratrol on lipid 
accumulation in the glomerulus, we performed oil red O 
staining of frozen renal tissue.
Light microscopy
Kidney samples were fixed in 10 % buffered formalin and 
embedded in paraffin. Histology was assessed follow-
ing periodic acid–Schiff (PAS) staining. The mesangial 
matrix and glomerular tuft areas were quantified for each 
glomerular cross-section using PAS-stained sections as 
previously reported [16]. More than 30 glomeruli, cut 
through the vascular pole, were counted per kidney and 
the average was used for analysis.
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Immunohistochemistry and terminal deoxynucleotidyl 
transferase‑mediated dUTP nick‑end labeling (TUNEL) 
assay
For immunohistochemistry, 4-μm sections were depar-
affinized, hydrated in ethanol, treated with an antigen-
unmasking solution of 10  mmol/L sodium citrate buffer, 
pH 6.0, and washed with phosphate buffered saline (PBS). 
Sections were incubated with 3  % H2O2 in methanol to 
block endogenous peroxidase activity. Nonspecific bind-
ing was blocked with 10 % normal goat serum in PBS. Sec-
tions were incubated overnight with antibodies against 
transforming growth factor-β1 (TGF-β1) (1:100; R&D Sys-
tems, Minneapolis, MN, USA), type IV collagen (Col IV) 
(1:200; Biodesign International, Saco, ME, USA), F4/80 
(1:50; Serotec, Oxford, UK), or 8-OH-dG (1:100; Cosmo-
Bio, Tokyo, Japan) in a humidified chamber at 4 °C. Anti-
body binding was visualized with peroxidase-conjugated 
secondary antibody using Vector Impress kits (Vector 
Laboratories, Burlingame, CA, USA) and 3,3-diaminoben-
zidine substrate solution. Sections were dehydrated in 
ethanol, cleared in xylene, and mounted without counter-
staining. All sections were examined in a blinded manner 
using light microscopy (Olympus BX-50, Olympus Opti-
cal, Tokyo, Japan). Col IV expression was detected using a 
tyramide signal amplification fluorescence system (Perki-
nElmer, Waltham, MA, USA). The proportion of apoptotic 
cells was determined using ApopTaq In  Situ Apoptosis 
Detection kits (Chemicon-Millipore, Billerica, MA, USA), 
based on the TUNEL assay. To quantify staining propor-
tions, approximately 20 views (×400 magnification) in the 
renal cortex and corticomedullary junction were randomly 
imaged from each slide and analyzed as density × positive 
area/glomerular total area using a computer image analysis 
program (Scion Image Beta 4.0.2, Frederick, MD, USA).
Western blots
With the total proteins from the renal cortical tissues 
from each groups as well as in  vitro cell lines, western 
assay was performed with specific antibodies for Adi-
poR1, AdipoR2, phospho-Thr172 AMPK, total AMPK, 
silent information regulator T1(SIRT1), PPARα, phos-
pho-Ser256 class O forkhead box (FoxO)1, total FoxO1, 
phospho-Ser253 FoxO3a, total FoxO3a, PPARγ coacti-
vator (PGC)-1α, estrogen-related receptor (ERR)-1α, 
sterol regulatory element-binding protein (SREBP)-1c, 
phosphorylated acetyl-CoA carboxylase (pACC), total 
ACC, phospho-Ser1177 endothelial nitric oxide synthase 
(eNOS), total eNOS, B cell leukemia/lymphoma 2 (Bcl-
2), Bcl-2-associated X protein (Bax) and β-actin (see the 
Additional file 1 for further details).
Cell culture and small interfering RNA (siRNA) transfection
Human glomerular endothelial cells (HGECs) were pur-
chased from Anigio-Proteomie (Boston, MA, USA) and 
subcultured in endo-growth media (Angio-Proteomie). 
The HGECs were then exposed to low glucose or high 
glucose, with or without the additional 6-h application 
of resveratrol (50  μM). siRNAs, targeted to AdipoR1 
and AdipoR2 and scrambled siRNA (siRNA cont) were 
complexed with transfection reagent (Lipofectamin 
2000; Invitrogen, Carlsbad, CA, USA), according to the 
manufacturer’s instructions. The proportion of apoptotic 
cells was determined using ApopTaq In  Situ Apopto-
sis Detection kits, based on the TUNEL assay. To quan-
tify staining proportions, approximately 20 views (×400 
magnification) were randomly imaged from each slide 
(see the Additional file 1 for further details).
Immunofluorescence analysis in the HGECs
To evaluate the effects of resveratrol on AdipoR1 and 
AdipoR2 expression, we performed immunofluorescence 
analysis for AdipoR1 (Abcam) and AdipoR2 (Abcam) in 
the HGECs using a tyramide signal amplification fluo-
rescence system (PerkinElmer) and counterstained with 
4,6-diamidino-2-phenylindole (DAPI).
Statistical analysis
Data are expressed as mean ±  standard deviation (SD). 
Differences between groups were examined for statistical 
significance using ANOVA with Bonferroni’s correction 
using SPSS version 11.5 (SPSS, Chicago, IL, USA). A p 
value <0.05 was considered significant.
Results
Physical and biochemical characteristics in mice
Body weight for the diabetic db/db and db/db Res mice 
was significantly higher than for nondiabetic db/m and 
db/m Res mice. Kidney weights did not differ between 
these groups. Fasting blood glucose and HbA1c were 
significantly higher for the db/db and db/db Res mice 
compared with the db/m and db/m Res mice. No differ-
ences between the groups in blood urea nitrogen and 
creatinine levels were observed. Albuminuria and urine 
volume were significantly increased in the db/db mice 
compared with the db/m and db/m Res mice. Resvera-
trol treatment ameliorated albuminuria and significantly 
decreased urine volume in db/db mice. In db/m mice, 
resveratrol treatment did not result in any change of the 
serum adiponectin level. In contrast, in db/db mice it 
slightly but significantly increased the serum adiponectin 
level (Table 1).
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Effects of resveratrol on renal phenotypes, TGF‑β1, Col IV 
and F4/80
There was a marked increase in the mesangial area in db/
db mice compared with db/m mice (Fig. 1a, b, **p < 0.01). 
Consistent with the change in the mesangial fractional 
area, expression of TGF-β1, which is associated with 
extracellular matrix Col IV expression, and inflamma-
tory cell infiltration in the glomerular area were sig-
nificantly increased in db/db mice compared with db/m 
mice (Fig.  1a, b, **p  <  0.01). All diabetes-induced renal 
phenotypic changes and inflammation shown in the db/
db mice were ameliorated with resveratrol treatment. 
No changes were noted between the db/m and db/m Res 
mice.
Renal cortical expression of AdipoR1 and AdipoR2, 
phospho‑Thr172 and total AMPK, SIRT1, PPARα, and FoxOs
The expression of AdipoR1 and AdipoR2 levels in the 
renal cortex was markedly decreased in db/db mice 
compared with db/m and db/m Res mice, as assessed by 
Table 1 Biochemical and physical characteristics of the study groups
Res resveratrol, FBS fasting blood sugar, HbA1c hemoglobin A1c, Cr creatinine, BUN blood urea nitrogen
* p < 0.001 compared with other groups, ** p < 0.05 compared with db/db control and p < 0.01 compared with db/m control and db/m Res
Db/m control Db/m Res Db/db control Db/db Res
Body weight (g) 30.6 ± 1.6 29.7 ± 2.0 40.3 ± 5.3* 41.8 ± 4.3*
Kidney weight (g) 0.19 ± 0.01 0.19 ± 0.03 0.21 ± 0.03 0.22 ± 0.02
FBS (mg/dL) 169 ± 53 180 ± 35 242 ± 49* 247 ± 91*
HbA1c (%) 4.1 ± 0.1 4.1 ± 0.1 12.2 ± 1.8* 12.7 ± 1.0*
BUN (mg/dL) 0.32 ± 0.05 0.35 ± 0.04 0.36 ± 0.03 0.37 ± 0.02
Serum Cr (mg/dL) 0.079 ± 0.008 0.081 ± 0.010 0.082 ± 0.011 0.080 ± 0.009
Serum adiponectin (μg/mL) 11.6 ± 1.0 11.8 ± 0.9 4.5 ± 0.4* 6.4 ± 0.5**
Urine volume (mL) 0.7 ± 0.2 0.8 ± 0.2 8.7 ± 2.2* 3.3 ± 1.1
24-h albuminuria (μg/day) 10.0 ± 4.2 9.0 ± 1.4 140.0 ± 34.2* 30.1 ± 15.5
Fig. 1 Changes in glomerular phenotypes in resveratrol-treated db/db mice. Glomerular mesangial fractional area, profibrotic TGF-β1, Col IV 
expression and F4/80-positive cell infiltration in the glomerulus of the cortical area of db/m and db/db mice with or without resveratrol treatment. a 
Representative sections stained with PAS reagent and immunohistochemical staining for TGF-β1, Col IV and F4/80-positive cells are shown (original 
magnification ×400). b Quantitative analyses of the results for the mesangial fractional area (%), TGF-β1, Col IV and F4/80-positive cells are shown. 
**p < 0.01 vs. db/m, db/m Res and db/db Res mice. Res resveratrol, PAS periodic acid–Schiff, TGF-β1 transforming growth factor- β1, Col IV type IV 
collagen
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western blot (Fig. 2a, b, **p < 0.01). Resveratrol treatment 
restored AdipoR1 and AdipoR2 levels in db/db mice to 
the levels in db/m and db/m Res mice. Phospho-Thr172 
AMPK, a putative target of AdipoR1 and AdipoR2 and 
a principal downstream signal in the AdipoR1 pathway, 
and SIRT1 levels were significantly decreased in db/db 
mice compared with db/m mice (Fig.  2a, b). Interest-
ingly, resveratrol treatment in db/db mice significantly 
increased the renal cortical expression of Phospho-
Thr172 AMPK and SIRT1 (Fig. 2a, b, *p < 0.05 for AMPK 
and **p < 0.01 for SIRT1). Resveratrol did not affect the 
total AMPK expression in the renal cortex, suggesting 
that the alteration in AMPK phosphorylation was not 
the result of a reduction in total AMPK protein. The 
levels of PPARα, a principal downstream signal in the 
AdipoR2 pathway, were lower in the renal cortex of db/
db mice compared with db/m and db/m Res mice, as 
assessed by western blot, and improved with resveratrol 
treatment (Fig. 2a, b, **p < 0.01). We examined whether 
AMPK phosphorylation and PPARα activation influ-
enced downstream targets, specifically, phosphorylation 
of FoxOs in the kidney. Both phospho- Ser256 FoxO1 and 
Ser253 FoxO3a levels increased in db/db mice compared 
with db/m and db/m Res mice (Fig. 2c). Consistent with 
AMPK phosphorylation and PPARα activation, resvera-
trol treatment of db/db mice decreased the expression 
of both phosphorylated FoxO1 and FoxO3a in the renal 
cortex, resulting in increases of total FoxO1 and FoxO3a 
expression. This demonstrated that resveratrol positively 
regulates FoxO signaling in diabetic kidneys (Fig.  2c, 
#p < 0.001).
Altered renal expression of PGC‑1α, ERR‑1α, SREBP‑1c, 
pACC, and intrarenal NEFA and TG
The PGC-1α–ERR-1α pathway and the downstream sign-
aling SREBP-1c and pACC are primary targets of FoxOs 
and are critical for regulation of lipid metabolism and 
accumulation of lipids in the kidney (lipotoxicity). In db/
Fig. 2 AdipoR1 and AdipoR2, phospho-Thr172 and total AMPK, SIRT1, PPARα and FoxO expression in the renal cortex of db/m and db/db mice with 
or without resveratrol. Protein lysates (40 μg) from renal cortex were separated by SDS–PAGE and analyzed by western blot. a Representative results 
are shown for AdipoR1 and AdipoR2, phospho-Thr172 and total AMPK, SIRT1, PPARα and β-actin. b Quantitative analyses of areas for AdipoR1 and 
AdipoR2, SIRT1 and PPARα, all relative to β-actin and phospho-Thr172 AMPK/total AMPK. *p < 0.05 and **p < 0.01 vs. db/m, db/m Res and db/db 
Res mice respectively. c Representative results for phospho-Ser256 and total FoxO1 and phospho-Ser253 and total FoxO3a and β-actin; quantitative 
analyses are for phosphorylated relative to total protein. #p < 0.001 vs. db/m, db/m Res and db/db Res mice. Adipo R adiponectin receptor, AMPK 
5′-adenosine monophosphate-activated protein kinase, SIRT1 silent information regulator T1, PPARα peroxisome proliferator-activated receptorα, Res 
resveratrol, FoxO class O forkhead box
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db mice, PGC-1α and ERR-1α expression in renal cortex 
was significantly decreased compared with that in db/m 
and db/m Res mice. The SREBP-1c level in the renal cor-
tex of db/db mice was increased compared with that in 
db/m and db/m Res mice, while the expression of pACC 
was reciprocally decreased (Fig. 3a, **p < 0.01). Inactiva-
tion of PGC-1α–ERR-1α and the subsequent increase in 
SREBP-1c and reciprocal decrease in pACC expression 
Fig. 3 PGC-1α, ERR-1α, SREBP-1, pACC and intrarenal lipid levels in the renal cortex of the db/m and db/db mice with or without resveratrol. Protein 
lysates (40 μg) from renal cortexes were separated by SDS–PAGE and analyzed by western blot. a Representative results are for PGC-1α, ERR-1α, 
SREBP-1, pACC and β-actin and quantitative analyses of areas are for PGC-1α/β-actin, ERR-1α/β-actin, SREBP-1/β-actin, and pACC. *p < 0.05 and 
**p < 0.01 vs. db/m, db/m Res and db/db Res mice, respectively. b Quantitative analyses are for intrarenal NEFA, TG and total cholesterol concentra-
tions. **p < 0.01 and #p < 0.001 vs. db/m, db/m Res and db/db Res mice, respectively. c Oil red O staining from db/m and db/db mice with or without 
resverastrol (original magnification ×400). PGC-1α PPARγ co-activator 1α, ERR-1α estrogen-related receptor-1α, pACC phosphorylated acetyl-CoA 
carboxylase, SREBP 1c sterol regulatory element-binding protein 1c, Res resveratrol, NEFA nonesterified fatty acid, TG triacylglycerol
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were associated with increases in the NEFA and TG con-
tent of the renal cortex of db/db mice (Fig. 3b, **p < 0.01 
for NEFA and #p < 0.001 for TG). Conversely, resveratrol 
treatment reactivated PGC-1α–ERR-1α signaling, which 
decreased SREBP-1c and increased pACC expression in 
the renal cortex of db/db mice, accompanied by decreased 
NEFA and TG accumulation in the tissues. These data 
suggested that resveratrol treatment prevented lipotoxic-
ity in the kidneys of animal with type 2 diabetes. Oil red 
O staining of renal tissues showed no apparent lipid depo-
sition in the kidneys of db/m control mice, regardless of 
whether they received resveratrol. Conversely, resveratrol 
treatment inhibited the accumulation of oil red O-staina-
ble lipid in the glomerulus in db/db mice (Fig. 3c).
Renal expression of eNOS, proapoptotic Bax, antiapoptotic 
Bcl‑2 and TUNEL‑positive cells
In db/db mice, consistent with inactivation of AMPK, 
PPARαα and FoxOs, the level of phospho-Ser1177 
eNOS decreased. It was restored by resveratrol treat-
ment, which thereby restored the phospho-Ser1177/
total eNOS ratio (Fig.  4a, *p  <  0.05). Also in db/db 
mice, Bax protein increased, whereas Bcl-2 protein 
decreased compared with db/m and db/m Res mice, 
resulting in an increase in TUNEL-positive cells in the 
kidneys (Fig. 4a, b, **p < 0.01 and #p < 0.001). Resvera-
trol treatment of db/db mice decreased Bax expression 
and reciprocally increased that of Bcl-2, leading to the 
restoration of the Bcl-2/Bax ratio, which was associated 
with a decrease in TUNEL-positive cells in the kid-
neys. These changes were consistent with the increased 
phosphorylation of eNOS in db/db and db/db Res mice, 
which attenuated apoptotic cell death in renal cells of 
diabetic animals.
Effects of resveratrol on renal and 24‑h urinary 8‑OH‑dG 
and isoprostane
We evaluated the oxidative stress and lipid peroxidation 
caused by renal damage in type 2 diabetes using renal and 
24-h urinary 8-OH-dG and 24-h urinary 8-isoprostane 
levels. In db/db mice, renal and 24-h urinary 8-OH-dG 
and 24-h urinary 8-isoprostane levels were significantly 
elevated compared with those of db/m mice (Fig.  5a–c, 
*p  <  0.05 and **p  <  0.01). Resveratrol treatment of db/
db mice significantly diminished both renal and urinary 
8-OH-dG and urinary 8-isoprostane. These findings sug-
gested that the exacerbated renal oxidative stress and 
lipid peroxidation in type 2 diabetic db/db mice could be 
ameliorated by resveratrol.
In vitro studies
Next, we examined whether resveratrol treatment of 
HGECs could upregulate the expression of AdipoR1 
and AdipoR2 under conditions of high-glucose-induced 
oxidative stress. Immunofluorescence analysis showed 
that the expression of AdipoR1 and AdipoR2 was lower 
in high-glucose (30 mmol/L d-glucose) medium than in 
low-glucose (5 mmol/L d-glucose) medium. Interestingly, 
resveratrol treatment significantly increased the AdipoR1 
and AdipoR2 expression of HGECs in high-glucose con-
ditions, but not in low-glucose conditions (Fig.  6a). We 
also examined whether resveratrol-mediated AdipoR1 
and AdipoR2 activation of HGECs resulted in activation 
of AMPK, PPARα and FoxOs. HGECs exposed to high-
glucose medium significantly decreased the expression 
of AdiopoR1 and AdipoR2 and their downstream signal-
ing, i.e., phospho-Thr172 AMPK, total FoxO1 and FoxO3a 
Fig. 4 Expression of eNOS, proapoptotic Bax and antiapoptotic 
Bcl-2 in the renal cortex of db/m and db/db mice with or without 
resveratrol. Protein lysates (40 μg) from renal cortexes were separated 
by SDS–PAGE and analyzed by western blot. a Representative results 
are for phospho-Ser1177 and total-eNOS, Bax, Bcl-2 and β-actin and 
the quantitative analyses are for the phospho-Ser1177/total-eNOS ratio 
and Bcl-2/Bax ratio. *p < 0.05 and **p < 0.01 vs. db/m, db/m Res and 
db/db Res mice mice, respectively. b Representative immunohisto-
chemical staining for TUNEL-positive cells with quantitative analysis. 
#p < 0.001 vs. db/m, db/m Res and db/db Res mice. eNOS endothelial 
nitric oxide synthase, Bcl-2 B cell leukemia/lymphoma 2, Bax Bcl-
2-associated X protein, Res resveratrol, TUNEL terminal deoxynucleoti-
dyl transferase dUTP nick end labeling
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(Fig. 6b, c). Consistent with the in vivo studies, resvera-
trol reversed the high-glucose-induced changes to the 
values seen with low-glucose medium.
Previous studies showed that AdipoR1 activates AMPK 
phosphorylation and AdipoR2 activates PPARα in the 
liver and muscle [17, 18]. Therefore, we evaluated the 
role of adiponectin receptors in mediating the activation 
of the downstream molecules, AMPK, SIRT1, PPARα, 
PGC-1α, and FoxOs, in resveratrol-treated HGECs that 
were cultured in high-glucose medium. For this, we per-
formed additional experiments using siRNAs against 
AdipoR1 and AdipoR2. The siRNAs could efficiently block 
the expression of both AdipoR1 and AdipoR2 (Addi-
tional file  2: Figure S1). The expressions of phosphoryl-
ated AMPK, SIRT1, PGC-1α, and PPARα in high-glucose 
medium-exposed HGECs were significantly attenuated 
by siRNA-mediated knockdown of AdipoR1 or AdipoR2 
in the cells (Fig.  7a). Next, we investigated the resver-
atrol-induced changes of AMPK, SIRT1, PGC-1α, and 
PPARα in high-glucose medium-exposed HGECs and 
underlying mechanisms. The results showed that resvera-
trol treatment in high-glucose medium-exposed HGECs 
can increase the activities of AMPK, SIRT1, PGC-1α, 
and PPARα in those cells and these effects were depend-
ent on AdipoR1 and AdipoR2 inducing properties of res-
veratrol (Fig.  7b, c). Furthermore, resveratrol treatment 
in HGECs exposed to high-glucose medium significantly 
increased the dephosphorylation of FoxO1 and FoxO3a, 
when compared with untreated cells (Fig.  7d). This is 
consistent with the in vivo results shown in Fig. 2c. Also, 
the FoxO signaling activation by resveratrol treatment 
was dependent on its AdipoR1 and AdipoR2 induc-
ing effects (Fig. 7d). In vivo studies (as shown in Fig. 4b) 
demonstrated the antiapoptotic effects of resveratrol in 
renal cells of type 2 diabetic db/db mice. Therefore, we 
investigated whether the antiapoptotic effect of resvera-
trol under high-glucose conditions was AdipoR1 or Adi-
poR2 dependent. The results showed that a decrease in 
TUNEL-positive cells in HGECs with resveratrol was 
significantly reversed by AdipoR1 and AdipoR2 siRNA 
treatment (Fig.  7e). These results suggested that resver-
atrol may increase the expression of both AdipoR1 and 
AdipoR2 in the kidney and consequently result in the 
activation of AMPK and PPARα and their downstream 
signals including PGC-1α and FoxOs.
Discussion
Deletion of the gene for adiponectin accelerates DN in 
Akita mice [19]. However, adiponectin reduces micro-
albuminuria and provides renoprotective effects by 
improving endothelial dysfunction and uncoupling the 
vascular endothelial growth factor–nitric oxide axis in 
rats with streptozotocin-induced type 1 diabetes [20]. 
Adiponectin also retards the progression of DN in db/
db mice by counteracting angiotensin II [21]. However, 
few therapeutic agents activate adiponectin, especially in 
the kidney [14, 22]. Therefore, we investigated resvera-
trol as a promising agent for preventing and treating DN 
through increasing AdipoR1 and AdipoR2 expression.
Resveratrol is an activator of AMPK–SIRT1–PPARα, 
a key to the regulation of lipids and glucose homeostasis 
and control of oxidative stress. Adiponectin is a 30-kDa 
circulating plasma protein primarily secreted by adipo-
cytes. Low circulatory levels seem to contribute to the 
pathophysiology of insulin resistance, type 2 DM and 
cardiovascular disease in obese or overweight patients 
or people with type 2 DM [8]. Resveratrol has benefi-
cial effects against development of albuminuria in ani-
mal experiments [5–7]. Ji et al. reported that resveratrol 
increases expression of AdipoR1 by activating FoxO1 in 
rats with streptozotocin-induced diabetes and mesangial 
cell cultures [14]. Another report found that decreased 
plasma adiponectin levels and renal expression of Adi-
poR1 but not AdipoR2 protein are associated with oxida-
tive stress in rats with streptozotocin-induced diabetes 
[23]. However, the effects of resveratrol on adiponectin 
receptors in the kidneys of individuals with type 2 DM 
are not well known.
Previously, we showed that resveratrol prevents DN via 
activation of the AMPK–SIRT1–PGC-1α axis and that 
Fig. 5 Intrarenal and 24-h urinary 8-OH-dG and isoprostane levels in 
db/m and db/db mice with or without resveratrol. a Representative 
immunohistochemical staining for 8-OH-dG and quantitative analysis. 
b **p < 0.01 vs. db/m, db/m Res and db/db Res mice. Levels of 24-h 
urinary 8-OH-dG (c) and isoprostane (d). *p < 0.05 and **p < 0.01 vs. 
db/m, db/m Res and db/db Res mice, respectively. 8-OH-dG 8-hydroxy-
2′-deoxyguanosine, Res resveratrol
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PPARα was activated by resveratrol in db/db mice [24]. 
These findings prompted us to investigate whether the 
renoprotective effect of resveratrol in DN was associated 
with adiponectin receptor activation, because AdipoR1 
activates the AMPK pathway and AdipoR2 activates the 
PPARα pathway. AdipoR1 is expressed predominantly 
in skeletal muscle and mediates fatty acid oxidation and 
glucose uptake by activating AMPK–SIRT1–PGC-1α and 
Ca2+ signaling pathways, which can be also activated by 
exercise. Both AdipoR1 and AdipoR2 are expressed in 
the liver and regulate glucose and lipid metabolism by 
activating the AMPK and PPARα pathways [17]. Sharma 
et  al. found that in the kidney, AdipoR1 is expressed to 
a similar degree as in liver, but AdipoR2 showed lower 
renal expression in in  vitro experiments using mouse 
podocytes [6]. This group also found that adiponectin 
administration activated AMPK and decreased albumi-
nuria by reducing oxidative stress. Guo and Zhao showed 
that AdipoR1 expression was significantly decreased in 
rats with streptozotocin-induced diabetes compared 
with controls, but there were no significant differences in 
AdipoR2 expression between the two groups, although 
expression in the diabetic group seemed lower than in 
controls [23]. These findings suggested that adiponectin 
exerts its effect in kidneys via AdipoR1 rather than Adi-
poR2. Okada-Iwabu et  al. demonstrated the efficacy of 
AdipoRon, an oral active AdipoR agonist, and showed 
that AdipoR1- and AdipoR2-knockout db/db mice had 
Fig. 6 a Immunofluorescence analysis was performed for AdipoR1 and AdipoR2 in the HGECs with or without resveratrol treatment (original 
magnification, ×400). Effect of resveratrol on intracellular signaling in HGECs cultured in low glucose (LG, 5 mmol/L of d-glucose) or high glucose 
(HG, 30 mmol/L of d-glucose) with or without resveratrol (50 μM). AdipoR1 and AdipoR2, phospho-Thr172 AMPK, total AMPK, phospho-Ser256 FoxO1, 
total FoxO1, phospho-Ser253 FoxO3a and total FoxO3a were assessed in HGECs. Protein lysates (10 μg) were separated by SDS–PAGE and analyzed 
by western blot. b Representative results for AdipoR1 and AdipoR2, phospho-Thr172 AMPK, total AMPK, phospho-Ser256 FoxO1 and total FoxO1, 
phospho-Ser253 FoxO3 and total FoxO3a and β-actin. c Quantitative analyses for AdipoR1/β-actin, AdipoR2/β-actin and phospho-Thr172 AMPK, 
phospho-Ser256 FoxO1 and phospho-Ser253 FoxO3a, all of which are relative to totals. *p < 0.05 and **p < 0.01 compared with LG, LG + Res, and 
HG + Res. HGECs human glomerular endothelial cells, AdipoR adiponectin receptor, AMPK 5′-adenosine monophosphate-activated protein kinase, 
FoxO class O forkhead box, LG low glucose, Res resveratrol, HG high glucose
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Fig. 7 The effect of resveratrol on the activities of AMPK–SIRT1–PGC-1α signaling, PPARα, FoxO, and apoptosis in HGECs exposed to high-glucose 
medium. Cultured HGECs in HG with or without resveratrol were transfected with 50 nmol/L control siRNA, 50 nmol/L AdipoR1 or AdipoR2 siRNA 
using transfection reagent (G-Fectin). Approximately 48 h after transfection, protein lysates (10 μg) were analyzed by Western blot for AdipoR1 
and AdipoR2, phospho-Thr172 AMPK, total AMPK, SIRT1, PGC-1α, and PPARα. a Representative results for phospho-Thr172 AMPK, total AMPK, SIRT1, 
PPARα, PGC-1α and β-actin and quantitative analyses for SIRT1, PPARα and PGC-1α relative to β-actin and phospho-Thr172 AMPK/total AMPK in 
HGECs exposed to high-glucose medium without resveratrol. **p < 0.01 compared with HG + siRNA control. b Representative results for Adi-
poR1 and AdipoR2, phospho-Thr172 AMPK, total AMPK, SIRT1, PPARα, PGC-1α and β-actin. c Quantitative analyses for AdipoR1 and AdipoR2, SIRT1, 
PPARα and PGC-1α relative to β-actin and phospho-Thr172 AMPK/total AMPK d Representative results for phospho-Ser256 FoxO1 and total FoxO1, 
phospho-Ser253 FoxO3a and total FoxO3a and β-actin and quantitative analyses for phospho-Ser256 FoxO1/total FoxO1 and phospho-Ser253 FoxO3a/
total FoxO3a. *p < 0.05 compared with HG + siRNA control. **p < 0.05 compared with HG + siRNA control and p < 0.01 compared with the other 
groups. e Representative immunohistochemical staining for TUNEL-positive HGECs with quantitative analysis. **p < 0.01 compared with the other 
groups. AdipoR adiponectin receptor, AMPK 5′-adenosine monophosphate-activated protein kinase, SIRT1 silent information regulator T1, PPARα 
peroxisome proliferator-activated receptorα, PGC-1α PPARγ co-activator 1α, HG high glucose, Res resveratrol, siRNA small interfering RNA, FoxO class 
O forkhead box
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a shorter survival than wild-type, AdipoR1 knockout or 
AdipoR2 knockout db/db mice [22]. In their study, Adi-
poR1-knockout db/db mice had shorter survival than 
AdipoR2-knockout mice and AdipoR2-knockout db/db 
mice had shorter survival than wild-type db/db mice. 
Yu et  al. showed that AdipoR1 and AdipoR2 expres-
sion in rats with CKD were significantly increased, as 
were serum and urine adiponectin levels [25]. Therefore, 
AdipoR1 and AdipoR2 activation appears to contrib-
ute to protection against CKD progression including in 
DN, although AdipoR1 is more highly expressed than 
AdipoR2 in kidneys and the relationship between renal 
expression of renal AdipoR1 and AdipoR2 and renal 
function is biphasic. A negative relationship exists in the 
early stages of DN such as microalbuminuria, and a posi-
tive association in more advanced renal damage, indicat-
ing that the counteracting upregulation of renal AdipoR1 
and AdipoR2 mitigates renal damage [26].
In this study, we found that DN in type 2 DM was 
characterized by suppression of AdipoR1, AdipoR2 and 
AMPK–SIRT1–PPARα expression, and inactivation of 
FoxO1 and FoxO3a. Together, these effects led to lipo-
toxicity, endothelial dysfunction, oxidative stress and 
increased apoptosis in the kidney. Resveratrol treatment 
reversed these changes, improving function and pheno-
types such as albuminuria and mesangial expansion and 
inflammation. In addition, in HGECs, which express both 
AdipoR1 and AdipoR2, resveratrol treatment reversed the 
high-glucose-induced decreases in the expression of Adi-
poR1 and AdipoR2 and their downstream signals, such as 
AMPK–SIRT1, PPARα, PGC-1α, and FoxOs to the levels 
observed in low-glucose medium. There is controversy 
whether resveratrol first induces AdipoR1 and AdipoR2, 
which then activate the AMPK–SIRT1–PGC1α pathway, 
or whether resveratrol activates FoxOs, which are respon-
sible for AdipoR1 and AdipoR2 expression. In the current 
study, we used AdipoR1 siRNA and AdipoR2 siRNA to 
clarify the effect of resveratrol on the expression of AMPK 
and FoxOs. The results showed that resveratrol-induced 
expression of AMPK and of FoxO1 and FoxO3a expres-
sions was decreased by AdipoR1 siRNA and AdipoR2 
siRNA, respectively. Therefore, we suggest that the pro-
tective role of resveratrol seems to be mediated through 
direct activation of both AdipoR1 and AdipoR2, which in 
turn increases the expression of AMPK and FoxOs.
In our study, AdipoR1 and AdipoR2 expression 
decreased and AMPK and PPARα were inactivated in db/
db mice. Conversely, resveratrol administration restored 
AdipoR1 and AdipoR2 expression and activated AMPK–
SIRT1–PGC-1α, which decreased phosphorylation of 
FoxO1 and FoxO3a [27]. In that study, Tsuchida et  al. 
demonstrated that AdipoR1 and AdipoR2 expression 
is controlled via the FoxO1 pathway in skeletal muscle 
and adipose tissue in mice with streptozocin-induced 
diabetes. FoxOs, downstream effectors shared by both 
AMPK–SIRT1–PGC-1α signaling and PPARα activa-
tion, may explain this interaction [28, 29]. We and others 
demonstrated that diabetic conditions, which are usu-
ally associated with increased TGF-β levels, induce PI3 K 
and Akt activation, leading to FoxO3a phosphorylation 
and its nuclear exclusion and inactivation in both strep-
tozotocin-induced type 1 diabetes and type 2 diabetic 
db/db mice [2, 30]. In our study, activation of PGC-1α–
ERR-1α–pACC and suppression of SREBP-1c decreased 
lipotoxicity, oxidative stress and apoptosis in kidneys. 
Studies of DN in human and animals showed that accu-
mulation of lipids in the kidney and lipotoxicity might 
be related to oxidative stress and apoptosis and possibly 
involved in diabetic CKD pathogenesis-related FoxO 
inactivation [2, 31, 32].
Decreased plasma adiponectin levels are associated 
with obesity, insulin resistance and type 2 DM. Replen-
ishment of adiponectin decreases insulin resistance, 
glucose intolerance and tissue triglyceride content by 
increasing fatty acid oxidation and decreasing oxida-
tive stress and inflammation [22]. Adiponectin is criti-
cal in the development of alcoholic fatty liver disease. 
In a study by Ajmo et  al., resveratrol protected against 
alcoholic fatty liver disease in mice by activating AMPK–
SIRT1–PGC-1α and increasing hepatic AdipoR1/R2 
expression [13]. Therefore, adiponectin and its receptors 
including AdipoR1 and AdipoR2 might be involved in 
lipid metabolism in the kidney as well as in adipose tis-
sue and the liver. However, a number of serious concerns 
have been raised about adiponectin as a therapeutic 
agent for diabetes and its complications. Overexpres-
sion of adiponectin in genetically engineered mice and 
stimulators of adiponectin secretion such as thiazoli-
dinediones [33] and fibroblast growth factor 21 [34] are 
associated with reduced bone density, heart damage (left 
ventricular hypertrophy), weight gain from promot-
ing adipogenesis and angiogenesis [35], and infertility 
[36]. Therefore, resveratrol may be a good candidate for 
increasing adiponectin levels and activating adiponec-
tin actions in patients with type 2 diabetic CKD without 
potential side effects. Another interesting finding in this 
study was the lack of effect of resveratrol on AdipoR1 
and AdipoR2 expression in db/m mice or in low-glu-
cose conditions, but its ability to restore AdipoR1 and 
AdipoR2 expression in db/db mice or in high-glucose 
condition. It has been reported that resveratrol usu-
ally has protective roles in DN only when adiponectin 
receptor expression is decreased [14]. Although its exact 
mechanisms of action are still controversial, resveratrol-
induced AMPK activation appears to be dose, time, and 
stress dependent [37, 38].
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Conclusions
The results of this study indicated that resveratrol 
increased circulating adiponectin levels and protected 
against DN by ameliorating inflammation, oxidative 
stress, apoptosis and endothelial dysfunction via activat-
ing AMPK–SIRT1–PPARα through AdipoR1 and Adi-
poR2. The results supported in vitro data in HGECs that 
upregulation of AdipoR1 and R2 by resveratrol in cells 
grown in high-glucose media could be a key response 
that protects against glucolipotoxicity in the kidney. 
These results suggest that resveratrol may be a promising 
therapeutic agent for type 2 DN.
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